Multidisciplinary Cardiovascular Annals

Published by: Kowsar

Safety of Adenosine for Acute Pulmonary Vasoreactivity Testing in Pulmonary Hypertension

Ahmad Amin 1 , * , Hossein Navid 1 , Mitra Chitsazan 1 , Bahar Ghaleshi 1 , Sepideh Taghavi 1 and Nasim Naderi 1
Authors Information
1 Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
Article information
  • Multidisciplinary Cardiovascular Annals: October 2016, 7 (1); e9324
  • Published Online: September 26, 2016
  • Article Type: Research Article
  • Received: August 1, 2016
  • Accepted: September 20, 2016
  • DOI: 10.17795/mcardia.9324

To Cite: Amin A, Navid H, Chitsazan M, Ghaleshi B, Taghavi S, et al. Safety of Adenosine for Acute Pulmonary Vasoreactivity Testing in Pulmonary Hypertension, Multidiscip Cardio Annal. 2016 ; 7(1):e9324. doi: 10.17795/mcardia.9324.

Abstract
Copyright © 2016, Iranian Society of Cardiac Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
References
  • 1. Hatano S, Strasser T. Primary pulmonary hypertension. 1975;
  • 2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5): 343-9[PubMed]
  • 3. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327(2): 76-81[DOI][PubMed]
  • 4. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111(23): 3105-11[DOI][PubMed]
  • 5. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30(20): 2493-537[DOI][PubMed]
  • 6. Groves BM, Badesch DB, Turkevich D, Ditchey RV, Donnellan K, Wynne K, et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. Ion flux in pulmonary vascular control. 1993; : 317-30
  • 7. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009; 53(17): 1573-619[DOI][PubMed]
  • 8. Ahn JH, Kang BJ, Hong SI, Lee JS, Lee JS, Oh YM, et al. Clinical characteristics and survival of Korean idiopathic pulmonary arterial hypertension patients based on vasoreactivity. J Korean Med Sci. 2014; 29(12): 1665-71[DOI][PubMed]
  • 9. Oliveira EC, Ribeiro AL, Amaral CF. Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide. Respir Med. 2010; 104(4): 606-11[DOI][PubMed]
  • 10. Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J. 2009; 33(6): 1354-60[DOI][PubMed]
  • 11. Milger K, Felix JF, Voswinckel R, Sommer N, Franco OH, Grimminger F, et al. Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. Pulm Circ. 2015; 5(2): 305-12[DOI][PubMed]
  • 12. Sompradeekul S, Wattanasiriphakdee S. Hemodynamic effect of iloprost inhalation and oral sildenafil during acute vasoreactivity test in pulmonary arterial hypertension. J Med Assoc Thai. 2015; 98(2): 144-9[PubMed]
  • 13. Pelleg A, Porter RS. The pharmacology of adenosine. Pharmacotherapy. 1990; 10(3): 157-74[PubMed]
  • 14. Watt AH, Penny WJ, Singh H, Routledge PA, Henderson AH. Adenosine causes transient dilatation of coronary arteries in man. Br J Clin Pharmacol. 1987; 24(5): 665-8[PubMed]
  • 15. Bush A, Busst CM, Clarke B, Barnes PJ. Effect of infused adenosine on cardiac output and systemic resistance in normal subjects. Br J Clin Pharmacol. 1989; 27(2): 165-71[PubMed]
  • 16. McCormack DG, Clarke B, Barnes PJ. Characterization of adenosine receptors in human pulmonary arteries. Am J Physiol. 1989; 256(1 Pt 2)-6[PubMed]
  • 17. Morgan JM, McCormack DG, Griffiths MJ, Morgan CJ, Barnes PJ, Evans TW. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation. 1991; 84(3): 1145-9[PubMed]
  • 18. Reeves JT, Groves BM, Weir EK. Adenosine and selective reduction of pulmonary vascular resistance in primary pulmonary hypertension. Circulation. 1991; 84(3): 1437-9[PubMed]
  • 19. Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest. 1995; 107(1): 54-7[PubMed]
  • 20. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol. 1992; 19(5): 1060-4[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments